ShuYu Civilian Pharmacy Corp., Ltd. (SHE:301017)
China · Delayed Price · Currency is CNY 15.87
+0.20 (1.28%)
At close: Feb 27, 2026
SHE:301017 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 9,855 | 9,487 | 9,122 | 7,709 | 5,286 | 4,624 |
Other Revenue | 83.26 | 83.26 | 69.51 | 114.13 | 35.25 | 16.16 |
| 9,938 | 9,570 | 9,191 | 7,823 | 5,322 | 4,640 | |
Revenue Growth (YoY) | 2.09% | 4.13% | 17.49% | 47.00% | 14.70% | 33.84% |
Cost of Revenue | 7,526 | 7,158 | 6,597 | 5,592 | 3,806 | 3,267 |
Gross Profit | 2,412 | 2,412 | 2,594 | 2,231 | 1,515 | 1,373 |
Selling, General & Admin | 2,386 | 2,392 | 2,259 | 1,812 | 1,330 | 1,032 |
Research & Development | - | - | - | 0.05 | - | - |
Other Operating Expenses | 19.36 | 20.14 | 19.81 | 16.57 | 12.47 | 21.43 |
Operating Expenses | 2,432 | 2,426 | 2,302 | 1,849 | 1,342 | 1,054 |
Operating Income | -20.19 | -13.93 | 291.99 | 381.8 | 173.57 | 318.78 |
Interest Expense | -127.79 | -138.88 | -118.33 | -73.43 | -31.98 | -6.61 |
Interest & Investment Income | 10.62 | 12.23 | 13.79 | 11.18 | 13.56 | 7.45 |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | -0.01 | - | - | - |
Other Non Operating Income (Expenses) | -38.49 | -35.58 | -11.96 | -11.95 | -25.34 | -46.28 |
EBT Excluding Unusual Items | -175.84 | -176.14 | 175.5 | 307.59 | 129.8 | 273.35 |
Impairment of Goodwill | -48.88 | -48.88 | - | - | - | - |
Gain (Loss) on Sale of Investments | 136.28 | 8.48 | 0.07 | 0.11 | 24.82 | -0.66 |
Gain (Loss) on Sale of Assets | 27.83 | 22.65 | 10.25 | 2.08 | -0.71 | 0.04 |
Legal Settlements | - | - | -0.61 | - | -9.26 | - |
Other Unusual Items | -19.45 | -19.45 | -7.6 | 10.77 | 5.81 | 19.87 |
Pretax Income | -61.47 | -213.34 | 177.59 | 320.55 | 150.46 | 292.6 |
Income Tax Expense | 14.18 | -8.33 | 37.54 | 87.3 | 36.14 | 73.05 |
Earnings From Continuing Operations | -75.65 | -205.01 | 140.05 | 233.24 | 114.32 | 219.54 |
Minority Interest in Earnings | 9.18 | 16.2 | -6.99 | -3.81 | 0.6 | -3.19 |
Net Income | -66.47 | -188.81 | 133.06 | 229.43 | 114.92 | 216.35 |
Net Income to Common | -66.47 | -188.81 | 133.06 | 229.43 | 114.92 | 216.35 |
Net Income Growth | - | - | -42.00% | 99.64% | -46.88% | 94.59% |
Shares Outstanding (Basic) | 375 | 402 | 403 | 403 | 383 | 367 |
Shares Outstanding (Diluted) | 375 | 402 | 403 | 403 | 383 | 367 |
Shares Change (YoY) | -12.66% | -0.37% | 0.17% | 5.07% | 4.47% | -1.06% |
EPS (Basic) | -0.18 | -0.47 | 0.33 | 0.57 | 0.30 | 0.59 |
EPS (Diluted) | -0.18 | -0.47 | 0.33 | 0.57 | 0.30 | 0.59 |
EPS Growth | - | - | -42.10% | 90.00% | -49.15% | 96.67% |
Free Cash Flow | 680.9 | 315.78 | -38.64 | 37.99 | 100.92 | 40.47 |
Free Cash Flow Per Share | 1.81 | 0.79 | -0.10 | 0.09 | 0.26 | 0.11 |
Dividend Per Share | - | - | 0.050 | 0.115 | 0.073 | 0.110 |
Dividend Growth | - | - | -56.52% | 57.53% | -33.64% | - |
Gross Margin | 24.27% | 25.21% | 28.22% | 28.52% | 28.47% | 29.59% |
Operating Margin | -0.20% | -0.15% | 3.18% | 4.88% | 3.26% | 6.87% |
Profit Margin | -0.67% | -1.97% | 1.45% | 2.93% | 2.16% | 4.66% |
Free Cash Flow Margin | 6.85% | 3.30% | -0.42% | 0.49% | 1.90% | 0.87% |
EBITDA | 47.1 | 53.6 | 359.83 | 440.06 | 219.28 | 357.33 |
EBITDA Margin | 0.47% | 0.56% | 3.91% | 5.63% | 4.12% | 7.70% |
D&A For EBITDA | 67.29 | 67.52 | 67.83 | 58.26 | 45.71 | 38.54 |
EBIT | -20.19 | -13.93 | 291.99 | 381.8 | 173.57 | 318.78 |
EBIT Margin | -0.20% | -0.14% | 3.18% | 4.88% | 3.26% | 6.87% |
Effective Tax Rate | - | - | 21.14% | 27.24% | 24.02% | 24.97% |
Revenue as Reported | 9,938 | 9,570 | 9,191 | 7,823 | 5,322 | 4,640 |
Advertising Expenses | - | 31.8 | 41.64 | 36.79 | 29.62 | 18.11 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.